In conclusion, this study showed that HH pathway is a survival signaling that drives LAC cell growth under stress conditions, and HHIP is a key regulator to block the induction of HH pathway. Targeting the HH pathway through inhibitors or HHIP thus holds promise to address EGFR-TKI resistance in LAC in clinic.
PMID: 27015549 [PubMed – as supplied by publisher] (Source: Oncotarget)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.